Involvement of RNA Polymerases I and III in Cancer Progression (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 21 March 2025 | Viewed by 1015
Special Issue Editor
Interests: cancer; industrial biotechnology; RNA polymerase III; transcription; tRNA genes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are excited to invite you to contribute to this Special Issue, which is the second edition of "Involvement of RNA Polymerases I and III in Cancer Progression" (https://www.mdpi.com/journal/cancers/special_issues/RNAIAIII).
The active synthesis of rRNA and tRNA by RNA polymerases (pols) I and III is a fundamental determinant of a cell’s capacity to grow. Most if not all cancers are likely to express abnormal levels of rRNAs and tRNAs. Multiple molecular mechanisms have been shown to contribute to this deregulation, including the aberrant expression of specific transcription factors, the activation of oncogenic signalling pathways, direct targeting by oncogene products, and the loss of restraint by key tumour suppressors. Far less is known about the consequences of these changes, although a growing body of evidence has implicated specific tRNAs in promoting metastasis. Furthermore, the deep sequencing of cancer genomes on a massive scale has implicated in tumorigenesis several other noncoding RNA genes that are transcribed by pol III, such as the RMRP gene. Strategies to manipulate pol III as a therapeutic target remain at early preclinical stages, but a specific inhibitor of pol I has reached clinical trials for solid and haematological malignancies.
This Special Issue aims to consider the involvement of pols I and III in cancer initiation, progression, and maintenance, including the roles of their individual ncRNA products. Related topics of interest include the molecular mechanisms responsible for the aberrant function of pols I and III in tumours and the potential of targeting these essential enzymes for therapeutic intervention.
Prof. Dr. Robert J. White
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- RNA polymerase I
- RNA polymerase III
- rRNA
- tRNA
